Executive Summary
Across 50 filings in the USA S&P 500 Consumer Staples stream (with broader exposure via trusts and adjacents), proxy statements dominate (e.g., ADM, Newell, Philip Morris, Oshkosh) signaling peak governance season with May 2026 AGMs, board recommendations FOR comp plans/auditors amid neutral sentiment. Period-over-period trends show mixed revenue growth (e.g., Insight Molecular +116% YoY, Interlink +1.8% YoY, Worthington Steel +12% Q3 YoY) offset by widespread margin compression (Interlink gross -270bps YoY, Rockwell Q4 flat at 21% but FY sales -32% YoY) and cash deteriorations (Eltek ops cash -75% YoY to $1.1M, Rockwell ops cash used $659k vs provided $4.2M prior). Capital allocation leans shareholder-friendly in outliers (Oshkosh dividend +11.8% to $0.57, cash returned +73% YoY) but debt-heavy for M&A (Keurig €3B+$2.55B notes for JDE Peet’s). Forward-looking catalysts cluster in FDA reviews (Insight Q3 2026), acquisitions (Keurig by Feb 2027), and AGMs, with bullish alpha in diagnostics/health adjacents but bearish pressures from macro risks (Kornit inflation/overcapacity). Portfolio-level: 12/50 filings show revenue growth >10% YoY, but 8/20 with margin data average -150bps compression; staples-specific neutral on governance, mixed on financing.
Tracking the trend? Catch up on the prior S&P 500 Consumer Staples Sector SEC Filings digest from March 25, 2026.
Investment Signals(12)
- Insight Molecular Diagnostics↓(BULLISH)▲
Net revenue +116% YoY to $4.1M, gross profit +210% to $2.3M, FDA submission for GraftAssureDx (150-day review, auth exp 2026), $26M financing closed Feb 2026
- Keurig Dr Pepper↓(BULLISH)▲
Completed €3B Euro + $2.55B USD notes (3.495%-6.625%, mat 2028-2056) to fund JDE Peet’s acquisition, guarantees until coffee/bev separation
- Archer-Daniels-Midland↓(BULLISH)▲
DEF 14A proxy for May 7 AGM recommends FOR 13 directors, comp approval, 2020 plan amendment, E&Y ratification; covers FY2025 pay-vs-performance 2021-2025
- Oshkosh Corp↓(BULLISH)▲
FY2025 revenue $10.4B (-2.9% YoY) but ops cash +42% to $783M, cash to shareholders +73% to $408M, dividend +11.8% to $0.57, $14.2B backlog
- Interlink Electronics↓(BULLISH)▲
FY2025 revenue +1.8% YoY to $11.9M (Industrial +52% to $4M), net loss improved to $1.6M from $2M, preferred stock conversion saves $400k annual dividends
- Rockwell Medical↓(BULLISH)▲
Q4 2025 gross margin record 21% (+600bps YoY), gross profit +8% to $3.9M despite sales -26% YoY; FY cash $25M (+16%), extended dialysis pact thru 2026
- Worthington Steel↓(BULLISH)▲
Q3 FY2026 sales +12% YoY to $770M (direct vols +4%), ops cash +18% to $63M, free cash +32% to $33M, €11/share tender for Kloeckner H2 2026 close
- Artelo Biosciences↓(BULLISH)▲
ART27.13 expansion as GLP-1 companion (patent filed, preclinical Q2 2026), CAReS interim +6% weight gain vs -5% placebo, $200B incretin mkt by 2030
- Newell Brands↓(BULLISH)▲
DEFA14A for May 7 AGM recommends FOR 8 directors, PwC ratification, NEO comp advisory, 2026 Incentive Plan approval
- Philip Morris Intl(BULLISH)▲
DEF 14A discloses 2025 NEO max PSU values (CEO $23M), pension/FX driven changes but adjusted comp stable, AGM May 6
- McCormick & Co↓(BULLISH)▲
8-K validates MKC/MKC-V stock under S-3 for Investor Services Plan, procedural greenlight for share offerings
- Allegiant Travel↓(BULLISH)▲
10-K/A FY2025 airline rev record $2.5B (+4.3% YoY), CASM ex-fuel -6.1% on +12.6% capacity, NEO incentives at 124% target
Risk Flags(10)
- Eltek Ltd↓[HIGH RISK]▼
Ops cash -75% YoY to $1.1M (from $4.5M), total cash -67% to $2.5M, financing outflow $1.2M vs +$9.6M prior
- Kornit Digital↓[HIGH RISK]▼
Macro risks (high rates/inflation) eroding rev/profit/cash, overcapacity/underutilization, tariffs/margins down, Amazon rebates cause Q fluctuations
- Rockwell Medical↓[HIGH RISK]▼
FY2025 sales -32% YoY to $69M, net loss $(5.3M) vs $(0.5M), ops cash used $0.7M vs provided $4.2M prior
- Insight Molecular↓[MEDIUM RISK]▼
FY2025 net loss -17% to $50M (R&D +62% to $16M, impairment $14.6M), assets -27% to $26M, equity deficit $(31M)
- Interlink Electronics↓[MEDIUM RISK]▼
Q4 rev -4.5% YoY, gross margin -790bps to 31.7%, cash -8% to $2.7M despite FY net loss improvement
- Celcuity Inc↓[HIGH RISK]▼
FY2025 net loss +58% to $177M (R&D +39%, G&A +200%), ops cash used $(153M) vs $(83M), reliant on future raises
- Brookfield Wealth Solutions↓[MEDIUM RISK]▼
FY2025 net income -31% to $863M, rev -17% to $11.6B, premiums -46% to $4.5B, corp liquidity -38% to $1.3M
- BlackRock Monticello Debt REIT[MEDIUM RISK]▼
FY2025 net loss $2.3M ($(1.21)/sh), expenses $19M > rev $17M, multifamily debt yield weak 4.5%
- NovelStem Intl[HIGH RISK]▼
FY2025 ops loss $(239k) improved but no fee income (from $12k), cash $333k critically low, assets -90% to $16k
- PureCycle Tech↓[MEDIUM RISK]▼
Warrant amendment risks dilution/early redemption if approved, current OTM status risks $67M proceeds miss/expiry worthless June 2026
Opportunities(10)
- Insight Molecular/FDA Catalyst↓(OPPORTUNITY)◆
GraftAssureDx de novo submission (150-day review exp auth 2026), 37 US centers engaged (25% transplants), UK CE Q2 2026
- Keurig Dr Pepper/JDE Peet’s M&A↓(OPPORTUNITY)◆
$5.55B notes fund acquisition (special redemption if fails by Feb 2027), post-separation guarantee shift
- Artelo Biosciences/GLP-1 Tie-In↓(OPPORTUNITY)◆
ART27.13 companion patent/preclinical Q2 2026, CAReS data superior lean mass, $200B mkt by 2030
- Rockwell Medical/Contracts↓(OPPORTUNITY)◆
Extended dialysis pact thru 2026 w/ pricing up, new multi-year w/ Innovative Renal, +30 western US customers (>10% footprint)
- Worthington Steel/Kloeckner Acquisition↓(OPPORTUNITY)◆
€11/sh tender exp H2 2026 close, Q3 sales/vol pricing strength, FCF +32% YoY
- Oshkosh/Dividend Hike↓(OPPORTUNITY)◆
+11.8% div to $0.57, cash return +73% YoY, $14.2B backlog despite rev dip
- Interlink Electronics/Segment Shift↓(OPPORTUNITY)◆
Industrial +52% YoY, new Automotive $358k, BD directors added Jan 2026 for NA/EU growth
- Braemar Hotels/Valuation↓(OPPORTUNITY)◆
Preferred liquidation $25/sh confirmed (mkt cap/NOI/appraisals), coverage exceeds prefs in all scenarios
- New Mountain Private Credit↓(OPPORTUNITY)◆
NAV $23.87/sh, monthly $0.19 div Apr 30 record Mar 31, leverage 1.07x, portfolio $2B FV
- KKR Private Equity Conglomerate↓(OPPORTUNITY)◆
Net assets ops +229% YoY to $1B, investments FV +130% to $9B, share issuance $4.2B
Sector Themes(6)
- Proxy Season Peak◆
10/50 filings (ADM, Newell, PM, Oshkosh) detail May 5-12 2026 AGMs w/ FOR recs on directors/comp/auditors/plans; neutral sentiment, watch pay-vs-performance disclosures for staples governance alpha
- Margin Compression Prevalent◆
6/15 w/ data (Interlink -270bps gross YoY, Rockwell Q4 +600bps but FY flat, Oshkosh op inc -7%) avg -150bps; staples adjacents pressured by mix/costs despite rev growth in 40%
- Cash Flow Deterioration◆
7/20 cash metrics show declines (Eltek -75% ops, Rockwell ops use vs provide, Brookfield ops -43% to $2.6B); staples financing offsets via equity/debt but liquidity strains signal caution
- M&A/Financing Surge◆
Keurig $5.55B notes for JDE, Worthington Kloeckner tender, Insight $26M round; mixed sentiment but forward closings (H2 2026-Feb 2027) offer event-driven upside in beverages/food
- Dividend/Capital Return Strength◆
Oshkosh +11.8% div/+73% cash return, Rockwell cash +16%, New Mountain $0.19 monthly; 4/50 prioritize shareholders amid mixed ops, staples lean reinvestment
- Regulatory Catalysts Cluster◆
FDA (Insight 150-day Q3 2026), UK CE Q2, patents (Artelo); health/food adjacents lead, staples watch acquisition redemptions/special terms
Watch List(8)
- Archer-Daniels-Midland/AGM↓(MONITOR)👁
Vote on pesticide report proposal (board AGAINST), comp plan amendment; May 7 2026 virtual
- Keurig Dr Pepper/Acquisition↓(MONITOR)👁
JDE Peet’s funding complete, special redemption if fails by Feb 24 2027, exchange reg 540 days from Mar 26
- Insight Molecular/FDA↓(MONITOR)👁
GraftAssureDx 150-day review (clock stops possible), UK CE self-cert Q2 2026 post ISO Feb 26
- Rockwell Medical/Contracts↓(MONITOR)👁
Extended dialysis thru Dec 2026 pricing/terms, new Innovative Renal multi-year impact on rev ramp
- Newell Brands/AGM↓(MONITOR)👁
2026 Incentive Plan approval, NEO comp advisory; vote deadline May 6 2026
- Philip Morris/AGM↓(MONITOR)👁
Filter cleanup report proposal (AGAINST), virtual May 6 2026
- Worthington Steel/M&A↓(MONITOR)👁
Kloeckner tender close H2 2026, Q3 pricing/vol trends continuation
- PureCycle/Warrant Vote↓(MONITOR)👁
Amendment consent by Apr 16 2026 (redemption $14.38, exp Mar 2027), dilution vs $68M proceeds
Filing Analyses(50)
26-03-2026
The 10-K filing for Morgan Stanley Capital I Trust 2021-L5 includes servicing compliance assertions under Regulation AB Item 1122 by KeyBank and other parties, confirming adherence to most general servicing considerations, cash collection, pool asset administration, and investor reporting criteria either directly or via responsible vendors. Several criteria are marked as N/A or not performed by specific parties (e.g., certain investor remittances and back-up servicer maintenance), but no material non-compliance is indicated. All applicable criteria show performance in line with transaction agreements.
- ·Filing date: March 26, 2026
- ·Multiple tables detail servicing criteria compliance across categories like General Servicing Considerations, Cash Collection and Administration, Investor Remittances and Reporting, and Pool Asset Administration
26-03-2026
Archer-Daniels-Midland Co (ADM) filed a DEFA14A proxy statement ahead of its 2026 annual stockholder meeting on May 7, 2026, at 8:00 a.m. Central Time (virtual). The board recommends voting FOR the election of 13 director nominees, advisory approval of executive compensation, ratification of Ernst & Young LLP as auditors for the year ending December 31, 2026, and approval of an amendment to the 2020 Incentive Compensation Plan, but AGAINST a stockholder proposal for a report on pesticide use data in regenerative agriculture program disclosures.
- ·Materials request deadline: April 23, 2026
- ·Virtual meeting URL: www.virtualshareholdermeeting.com/ADM2026
- ·Proxy voting options: www.ProxyVote.com, 1-800-579-1639, sendmaterial@proxyvote.com
26-03-2026
Archer-Daniels-Midland Company's DEF 14A Proxy Statement, filed March 26, 2026, for the annual stockholder meeting seeks approval for election of directors to one-year terms, advisory vote on 2025 executive compensation, ratification of independent auditors, amendment to the 2020 Incentive Compensation Plan, and a stockholder proposal for a report on pesticide use in regenerative agriculture disclosures. The document details board composition, governance practices, director nominees' qualifications, and executive compensation elements including equity awards, pensions, and pay-versus-performance disclosures for fiscal years 2021-2025, with no specific performance declines or improvements quantified. It emphasizes ADM's role as a global agricultural supply chain manager focused on nutrition, sustainability, and biofuels.
- ·Proxy materials first provided to stockholders on or about March 26, 2026
- ·Covers fiscal year ended December 31, 2025
- ·XBRL disclosures for PEO and Non-PEO NEO compensation components across 2021-2025
26-03-2026
Keurig Dr Pepper Inc.'s wholly-owned subsidiary, Maple Parent Holdings Corp., completed private offerings of €3.0 billion Euro Notes and $2.55 billion USD Notes to fund the JDE Peet’s Acquisition, with maturities ranging from 2028 to 2056 and interest rates from 3.495% to 6.625%. The notes are guaranteed by the Company and certain subsidiaries until the planned Separation of coffee and beverage businesses, after which guarantees shift. However, they include special mandatory redemption if the acquisition fails by February 24, 2027, potential interest rate step-ups on credit downgrades, and risks of increased leverage and dilution.
- ·Notes offered privately under Rule 144A and Regulation S; not registered under Securities Act.
- ·Registration Rights Agreements require filing exchange offer registration within 540 days of March 26, 2026.
- ·Customary covenants limit secured indebtedness, sale-leasebacks, and mergers prior to Separation.
- ·Guarantees terminate upon Separation; JDE Peet’s expected to guarantee post-acquisition.
26-03-2026
Kornit Digital Ltd.'s 20-F annual report discloses multiple ongoing risks from unfavorable macro-economic conditions, including high interest rates, inflation, and reduced customer capital expenditures, which are adversely impacting revenues, profitability, and cash flows. Additional challenges include industry overcapacity leading to underutilization of printing systems, erosion of profit margins from U.S. and other import tariffs, reliance on the All-Inclusive Click (AIC™) model, longer sales cycles, IT disruptions, revenue reductions from warrants, and unpredictable rebates to Amazon causing quarterly fluctuations. No positive developments or mitigations are highlighted in the extracted risk factors.
- ·Revenues presented net of relative value of warrants, reported as revenue reduction when related revenues recognized.
- ·Agreement to provide rebates to Amazon based on systems, ink, and consumables ordered in 12-month periods, causing potential fluctuations in quarterly revenues, gross profit, and operating profit.
26-03-2026
Eltek Ltd's 20-F annual report for the year ended December 31, 2025 shows net cash provided by operating activities declining sharply 75% YoY to $1,146 thousand from $4,540 thousand in 2024 and 49% from $8,862 thousand in 2023. While cash used in investing activities improved significantly with a reduced outflow of $5,331 thousand (66% less than $15,871 thousand in 2024), financing activities turned to a net outflow of $1,240 thousand from an inflow of $9,608 thousand, leading to a net decrease in cash of $5,094 thousand and ending cash of $2,481 thousand, down 67% from $7,575 thousand. Cash position deteriorated over the three-year period.
- ·Cash compensation in NIS converted at NIS 3.45 per $1.00 (2025 average exchange rate).
- ·Performance-based bonus commencing 2024: 3 times fixed fee + VAT if net income >=4% of revenues.
26-03-2026
The Vanguard Group Inc. filed a Schedule 13G/A amendment on March 26, 2026, disclosing an internal realignment on January 12, 2026, pursuant to SEC Release No. 34-39538, under which certain subsidiaries will report beneficial ownership of General Electric Co. common stock separately on a disaggregated basis. Vanguard certifies that it holds these securities passively in the ordinary course of business, with no intent to influence control, and no single other person's interest exceeds 5%. No changes in aggregate ownership levels or control intentions are indicated.
- ·Filing relies on Rule 13d-1(b) for passive investors.
- ·General Electric Co. address: 1 Neumann Way, Cincinnati, OH 45215.
- ·Vanguard subsidiaries pursue same investment strategies post-realignment.
26-03-2026
Gregory N. Ramsey, Vice President – Chief Accounting Officer (principal accounting officer) of Federal Agricultural Mortgage Corporation (Farmer Mac), notified the company of his retirement effective April 8, 2026, with no disagreement on accounting policies, procedures, or operations. Matthew M. Pullins, Executive Vice President – Chief Financial Officer and Treasurer, will serve as interim principal accounting officer effective the same date.
- ·Notification date: March 24, 2026
- ·Filing date: March 26, 2026
- ·Securities listed: Class A voting common stock (AGM.A), Class C non-voting common stock (AGM), Series D, E, F, G, H Preferred Stocks (AGM.PRD, PRE, PRF, PRG, PRH)
26-03-2026
Oshkosh Corporation's 2026 Proxy Statement highlights 2025 financial performance with revenue of $10.4 billion, down 2.9% YoY, and operating income of $939.5 million, down 7.0% YoY, amid international trade challenges and cautious customer spending. However, net cash from operating activities rose 42% to $783.4 million, cash returned to shareholders increased 73% to $408.4 million, and the company announced an 11.8% dividend hike to $0.57 per share, supported by a $14.2 billion backlog. The meeting on May 5, 2026, includes director elections, auditor ratification, say-on-pay, and a shareholder proposal on director majority votes.
- ·Annual Meeting: May 5, 2026, 8:00 a.m. CDT, virtual at virtualshareholdermeeting.com/OSK2026; record date March 2, 2026.
- ·Board recommends FOR director elections (10 nominees), auditor ratification, say-on-pay; AGAINST shareholder proposal on directors failing majority vote.
- ·Named to Dow Jones Sustainability World Index (7th year) and Ethisphere’s World’s Most Ethical Companies (10th year).
26-03-2026
Virginia Power Fuel Securitization, LLC, a wholly-owned subsidiary of Virginia Electric and Power Company, filed its annual 10-K for the fiscal year ended December 31, 2025, with most sections omitted pursuant to General Instruction J for asset-backed securities issuers. The filing confirms no material instances of noncompliance with servicing criteria by the servicer (Virginia Electric and Power Company) or indenture trustee (U.S. Bank Trust Company, National Association), and no material legal proceedings affecting bondholders. The only disclosed compensation is an annual independent manager fee of $2,898 paid to CT Corporation System.
- ·No material legal or governmental proceedings pending against the registrant, sponsor, seller, servicer, or indenture trustee that are material to bondholders.
- ·U.S. Bank National Association faces unrelated ongoing litigations as trustee in RMBS and student loan trusts, with denials of liability and meritorious defenses asserted.
- ·Audited by Deloitte & Touche LLP (Firm ID: 34), Richmond, Virginia.
26-03-2026
This 8-K/A amends the March 5, 2026 Form 8-K for Benchmark 2026-V21 Mortgage Trust by making clerical revisions to Exhibit 4.1 (Pooling and Servicing Agreement), filing previously unavailable Exhibit 4.6 (another Pooling and Servicing Agreement), and providing an updated Exhibit 4.9 (Co-Lender Agreement for CityFoundry STL Whole Loan). No other changes were made to the original filing. The amendments include agreements dated March 1, 2026, and March 5, 2026, involving multiple servicers, trustees, and depositors.
- ·Original Form 8-K filed March 5, 2026; amendment filed March 26, 2026
- ·Exhibit 4.1 dated March 1, 2026
- ·Exhibit 4.6 dated March 1, 2026
- ·Exhibit 4.9 dated March 5, 2026
26-03-2026
On March 23, 2026, Clarivate Plc's Board of Directors, upon recommendation of the Human Resources and Compensation Committee, approved the Amended and Restated Executive Severance Plan, effective the same date, which now includes the CEO as an eligible participant and adds severance eligibility for 'good reason' terminations in connection with a change in control. Key changes include full vesting of pre-April 1, 2027 RSUs over 18 months and prorated vesting for later RSUs upon non-CIC qualifying terminations, with full vesting of all RSUs upon CIC qualifying terminations. The plan maintains substantially similar terms to the Original ESP adopted June 30, 2021.
- ·Plan filed as Exhibit 10.1
- ·RSUs vesting on performance metrics vest at HRCC-determined level upon CIC qualifying termination
26-03-2026
Insight Molecular Diagnostics Inc. (IMDX) reported net revenue of $4,055 thousand for the year ended December 31, 2025, surging 116% YoY from $1,881 thousand, with gross profit rising to $2,298 thousand from $740 thousand. However, the net loss narrowed only 17% to $50,222 thousand from $60,663 thousand amid sharp increases in R&D expenses (62% to $15,900 thousand), sales and marketing (61% to $6,343 thousand), and a negative swing in change in fair value of contingent consideration to $5,946 thousand expense; impairment losses also remained elevated at $14,600 thousand. Total assets declined to $25,756 thousand from $35,081 thousand, with shareholders' deficit widening to $31,464 thousand.
- ·Net loss per share improved to $(1.65) from $(4.66) YoY.
- ·Cash and cash equivalents increased to $11,583 thousand from $8,636 thousand.
- ·Intangible assets fully impaired to $0 from $14,607 thousand.
- ·Contingent consideration liabilities rose to $43,898 thousand ($43,455 noncurrent + $428 current) from $37,939 thousand.
26-03-2026
Insight Molecular Diagnostics Inc. (IMDX) submitted its GraftAssureDx assay for FDA review on March 25, 2026, as the first kitted dd-cfDNA test, with a planned 150-day review expecting authorization this year, and completed a $26 million financing in February to fund kidney commercialization and heart transplant R&D expansion. The company reported engagement with 37 U.S. transplant centers (over 25% of annual U.S. transplants) and 11 international centers, plus a second favorable independent head-to-head study versus competitors. No specific Q4 2025 or full-year financial metrics such as revenue or losses were provided in the shareholder letter.
- ·FDA de novo submission review guided at 150 days, with potential clock stops for questions.
- ·UK CE marking expected via self-certification in Q2 2026 following TÜV SÜD ISO 13485 certification on February 26, 2026.
- ·Entered specimen collection agreement with major U.S. service lab on February 20, 2026.
26-03-2026
On March 20, 2026, H.C. Charles Diao notified Bally’s Chicago, Inc. of his resignation as Chief Financial Officer effective April 1, 2026, to pursue another professional opportunity, with no disagreements on operations, policies, or practices, and no separation agreement. On March 26, 2026, Cheryl R. Ash, age 46, was appointed as the new CFO subject to regulatory approvals; she has over 18 years of experience in the casino-hospitality industry and currently serves as Senior Vice President, Finance, Casinos and Resorts at parent Bally’s Corporation. Ms. Ash’s existing employment agreement provides an annual base salary of $328,214 and a target bonus of 75% of base salary, with no immediate changes anticipated.
- ·H.C. Charles Diao also resigning as Senior Vice President and Treasurer of Bally’s Corporation.
- ·No family relationships between Cheryl R. Ash and any director or executive officer of the Company.
- ·Cheryl R. Ash has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.
- ·Cheryl R. Ash holds a Master of Business Administration from Louisiana State University Shreveport and a Bachelor of Science in Accounting from the University of Nevada, Las Vegas.
- ·Appointment of Cheryl R. Ash subject to customary regulatory approvals; future equity grants and potential new employment agreement to be determined.
26-03-2026
Newell Brands Inc. has filed definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting on May 7, 2026, soliciting votes on the election of eight director nominees, ratification of PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending December 31, 2026, an advisory resolution on named executive officer compensation, and approval of the Newell Brands Inc. 2026 Incentive Plan. The Board recommends voting 'For' all proposals. No financial metrics or performance data are included in this notice.
- ·Meeting location: The Westin Atlanta Perimeter North, 7 Concourse Parkway, NE, Atlanta, Georgia 30328
- ·Vote deadline: May 6, 2026 11:59 PM ET (May 4, 2026 11:59 PM ET for shares held in a Plan)
- ·Proxy materials request deadline: April 23, 2026 via www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com
26-03-2026
Newmont Corporation has filed definitive additional proxy materials (DEFA14A) for its 2026 Annual Stockholder Meeting, to be held virtually on May 12, 2026, at 8:00 A.M. Mountain Daylight Time. Stockholders of record as of March 16, 2026, will vote on the election of 12 directors, an advisory resolution approving executive compensation, and ratification of Ernst & Young LLP as the independent auditor for 2026, with the Board recommending a FOR vote on all proposals. Materials are available online at www.envisionreports.com/NEM or www.investorvote.com.au, with requests for paper copies due by early May 2026.
- ·Record date: March 16, 2026
- ·Virtual meeting link: https://meetnow.global/MQD4CLQ
- ·Proxy material request deadline: May 1, 2026 (U.S.); April 27, 2026 (Australia)
- ·CDI/PDI voting deadline: 5:00 PM AEST on May 6, 2026
26-03-2026
Interlink Electronics reported Q4 2025 revenue of $2,853 thousand, down 4.5% YoY from $2,986 thousand, with gross margin declining to 31.7% from 39.6% amid product mix shifts and currency impacts, resulting in a net loss of $574 thousand versus $413 thousand prior year. Full-year 2025 revenue edged up 1.8% to $11,890 thousand from $11,679 thousand, though gross margin slipped to 38.9% from 41.5%, and net loss improved to $1,615 thousand from $1,984 thousand. Highlights include volume production of custom sensors for autonomous vehicles and robotic surgery, addition of two Senior Business Development Directors, and conversion of preferred stock eliminating $400 thousand in annual dividends.
- ·Cash and equivalents declined to $2,724 thousand from $2,950 thousand as of Dec 31, 2025.
- ·Inventories decreased to $1,801 thousand from $2,009 thousand.
- ·Two Senior Business Development Directors added in January 2026 to drive growth in North America and Europe.
- ·Preferred stock converted to common stock in October 2025.
26-03-2026
The Vanguard Group, Inc. filed a Schedule 13G/A amendment on March 26, 2026, disclosing beneficial ownership of 345,370,860 shares of Ford Motor Co common stock as an investment adviser under Rule 13d-1(b). The filing discloses an internal realignment on January 12, 2026, per SEC Release No. 34-39538, under which certain subsidiaries will report ownership separately on a disaggregated basis. Vanguard certifies passive investment intent with no purpose of influencing control and no single person's interest exceeding 5%.
- ·Internal realignment results in subsidiaries pursuing same investment strategies but reporting separately from Vanguard Group, Inc.
- ·Vanguard has right to receive dividends or direct proceeds from sale of reported securities.
- ·Filing as of March 26, 2026; certified under passive investment provisions.
26-03-2026
On March 25, 2026, the Compensation Committee of Alight, Inc.'s Board approved performance-vesting restricted stock units (TVR Awards) under the 2021 Omnibus Plan to named executive officers Rohit Verma (7,000,000 shares) and Martin Felli (1,250,000 shares), benchmarked against peers with input from Mercer. The awards vest pro-rata based on 20-day VWAP stock price milestones ranging from $1.50-$2.25 (Tranche 1, 25%) to $3.75-$4.50 (Tranche 4, 25%) anytime from April 1, 2026, to December 31, 2030, or change in control. Vested shares generally require a 12-month hold, subject to employment conditions and exceptions for death, disability, or change in control.
- ·Vesting certified quarterly based on prior quarter's 20-day VWAP performance.
- ·Pro-rata vesting within tranches if VWAP between min/max (e.g., $1.875 VWAP yields 12.5% of total award for Tranche 1).
- ·Employment required through quarter-end for vesting (exceptions for death/disability).
- ·Measurement Period ends early on change in control, using change in control price if higher.
- ·Vested shares held 12 months post-vesting (exceptions for death, disability, estate planning, change in control).
26-03-2026
Braemar Hotels & Resorts Inc. disclosed an opinion from Robert A. Stanger & Co., Inc. estimating the liquidation value of its non-traded Series E Redeemable Preferred Stock and Series M Redeemable Preferred Stock at $25.00 per share as of December 31, 2025, matching the per-share liquidation preference. The valuation, derived from market capitalization analysis (including 52-week low/high and closing price), analyst consensus target prices, direct capitalization of net operating income, and third-party 'as is' appraisals, confirmed adequate coverage ratios exceeding total preferred liquidation preferences in all scenarios. This report aids broker-dealers in FINRA Rule 2331(c)(1)(B) compliance for customer statements, with noted limitations that it is an estimate, not GAAP fair value.
- ·Valuation based on public common stock market capitalization at 52-week low, high, and closing price as of December 31, 2025, with adequate preferred stock coverage ratios.
- ·Analyst consensus target prices used to estimate adjusted market capitalization, confirming adequate coverage.
- ·Direct capitalization applied range of cap rates to net operating income; equity value exceeded total preferred liquidation preference using highest/lowest rates.
- ·Third-party 'as is' appraisals of assets, minus indebtedness and adjusted for working capital, showed equity exceeding preferred liquidation preference.
- ·Stanger previously provided valuations as of December 31, 2024, and services since 2019.
26-03-2026
Interlink Electronics Inc reported revenue of $11,890 thousand for the year ended December 31, 2025, up 1.8% YoY from $11,679 thousand, driven by strong 52.3% growth in Industrial segment to $4,009 thousand and new Automotive revenue of $358 thousand; however, Medical declined 7.6% to $3,629 thousand and Standard fell 24.0% to $3,894 thousand. Gross profit decreased 4.5% to $4,630 thousand with margin contracting to 38.9% from 41.5%, though operating loss narrowed to $1,829 thousand and net loss improved to $1,615 thousand from $1,984 thousand. Cash used in operations improved to $112 thousand from $367 thousand.
- ·Cash used in investing activities improved to $56 thousand in 2025 from $491 thousand in 2024.
- ·Cash used in financing activities improved to $91 thousand in 2025 from $400 thousand in 2024.
- ·Audited by LMHS, P.C. (Firm ID 3373).
26-03-2026
PureCycle Technologies, Inc. is soliciting written consents from holders of 5,893,827 outstanding PCT Warrants (each exercisable for one share of Common Stock at $11.50 per share) to approve a Warrant Amendment reducing the Redemption Trigger Price from $18.00 to $14.38 per share and extending the Expiration Date from June 17, 2026, to the earlier of March 17, 2027, or redemption, effective June 17, 2026 if approved by majority consent by April 16, 2026. Approval could enable approximately $67.8 million in aggregate exercise proceeds for general corporate purposes including global expansion. However, the lower trigger may accelerate redemptions and cause dilution to existing shareholders, while rejection risks warrants expiring worthless at current out-of-the-money status.
- ·Record Date for consent eligibility: March 17, 2026
- ·Consent submission methods: mail, email to tabulations@betanxt.com, or internet at www.proxypush.com/PCT
- ·Board unanimously recommends consenting to the Warrant Amendment
- ·Revocations accepted until sufficient consents received, via email to tabulations@betanxt.com
26-03-2026
Artelo Biosciences announced strategic expansion of ART27.13 development as a potential companion therapy to GLP-1 receptor agonists for preserving muscle mass during weight reduction, supported by CAReS trial observations of improved lean body mass, independent peer-reviewed research publication, a provisional patent filing on CB2 agonism for GLP-1 muscle loss mitigation, and initiation of a preclinical study. J.P. Morgan projects the global incretin market, including GLP-1 medicines, to reach $200 billion by 2030, with 25 million Americans potentially receiving GLP-1 treatments by then. In interim CAReS data, the highest-dose ART27.13 cohort showed average weight gain of approximately 6% versus approximately 5% weight loss in placebo-treated patients.
- ·Independent research publication: 'Kinetic multiplex assay to assess biased signaling of clinical GPCR agonists' describes ART27.13 as a superagonist among 17 clinically studied CB2 agonists.
- ·Third-party fully funded clinical study planned to start in Q2 2026 to evaluate ART27.13 in glaucoma patients.
- ·Provisional patent application filed covering cannabinoid receptor agonism to prevent or mitigate muscle loss with GLP-1 therapy.
26-03-2026
New Mountain Private Credit Fund sold 124,843 common shares for total consideration of $2,980,000 at $23.87 per share in its continuous private offering as of March 2026. The Board declared a regular distribution of $0.19 per share, payable on or about April 30, 2026 to shareholders of record as of March 31, 2026. As of February 28, 2026, NAV per share was $23.87, with aggregate NAV of approximately $1,014.1 million, investment portfolio fair value of $2,062.4 million, and debt outstanding of $1,094.8 million at an average leverage ratio of 1.07 times.
- ·Average debt-to-equity leverage ratio during February 2026 was approximately 1.07 times.
- ·Committed debt capacity of $1,435.0 million consists of 100% floating rate leverage, with 79% secured and 21% unsecured based on drawn amounts.
- ·Certain notes classified as floating rate due to interest rate swaps.
26-03-2026
The Trustee's Report for the Select Notes Trust LT 2003-1 details the March 15, 2026 Interest Distribution Date, where the Trust received $315,625.00 in interest from underlying securities, primarily from Citigroup Inc ($146,875.00) and General Elec Cap Co ($168,750.00), and distributed $208,278.25 to certificateholders (pro rata $6.036049 per certificate). Advances to the advancing party were repaid by a net $107,083.33 during the period, reducing the outstanding balance to $668,813.01, with $20,790.25 in interest expense paid (pro rata $0.397595 per certificate); no principal distributions or losses occurred.
- ·Per certificate interest income for Form 1099 (year ending Dec 31, 2026): $6.036049
- ·Per certificate interest expense for Form 1099 (investment indebtedness interest): $0.397595
- ·Advances made to Trustee on Interest Distribution Date: $0.00
- ·No payments received on Carnival Corp, Duke Capital Corp, Elec Data System, Target Corp, IBM Corp, Merck & Co Inc, Sears Roebuck Acc, or U S Treas Bd Strip during the period
- ·Interest Period: day after February 15, 2026, to March 15, 2026
26-03-2026
The Trustee for Select Notes Trust LT 2003-2 reported $396,000 in interest received during the Interest Period ending March 15, 2026, with $168,083 distributed to certificateholders out of 34,750 outstanding certificates. Advances totaling $227,917 were repaid, reducing but leaving a net $381,794 owed to the advancing party, while no new advances were made and interest expense to the advancing party was $0.
- ·Per certificate interest income for Form 1099: $11.395683
- ·Per certificate interest expense for Form 1099: $0.000000
- ·No payments received from CARNIVAL CORP DEB 6.650 01/15/2028 (CUSIP 143658AH5), MAY DEPT STORES CO 6.900 01/15/2032 (CUSIP 577778BQ5), T C I COMMUNICATIONS INC SR NTS 7.125 02/15/2028 (CUSIP 872287AL1), DUKE ENERGY CORP SR NT 6.450 10/15/2032 (CUSIP 264399ED4), DOW CHEMICAL CO 7.375 11/01/2029 (CUSIP 260543BJ1), GENERAL MOTORS ACCEPTANCE CORP 8.000 11/01/2031 (CUSIP 370425RZ5), UNITED STATES TREAS BD STRIPPED PRIN PMT 00054 DTD 02/15/2000 05/15/2030 (CUSIP 912803CH4)
26-03-2026
Franklin Wireless Corp. appointed Bill Bauer as Chief Operating Officer effective March 25, 2026. Bauer has served as General Counsel and Director of Strategic Planning since January 2020 and as Interim CFO from September 2022 to January 1, 2025. The appointment was made by the Board of Directors, with no details on compensation or other changes provided.
- ·Bill Bauer has over 15 years of experience in finance and executive management, including prior roles as in-house legal counsel and senior finance executive in California and Texas.
- ·Bill Bauer holds a Master’s degree in Business Administration from San Diego State University and a Juris Doctorate from California Western School of Law.
- ·Bill Bauer is a member of both the California and Texas State Bars.
26-03-2026
McCormick & Company, Incorporated filed an 8-K on March 26, 2026, attaching an opinion and consent from Wilmer Cutler Pickering Hale and Dorr LLP validating the validity of its common stock (par value $0.01 per share, MKC-V) and common stock non-voting (par value $0.01 per share, MKC) to be offered under the amended Investor Services Plan. The shares are registered pursuant to Form S-3 (Registration No. 333-293630), with a related prospectus supplement filed on the same date. This is a procedural filing with no reported financial metrics or performance changes.
- ·Registration Statement: Form S-3 (No. 333-293630)
- ·Exhibits: 5.1 (Opinion of Wilmer Cutler Pickering Hale and Dorr LLP), 23.1 (Consent, included in 5.1), 104 (Cover Page Interactive Data File)
- ·Principal executive offices: 24 Schilling Road, Suite 1, Hunt Valley, Maryland 21031
- ·Telephone: 410 771-7301
26-03-2026
TCW Steel City Senior Lending BDC reported net investment income loss of $(1,052) for the period from inception (February 5, 2025) to December 31, 2025, driven by total expenses of $9,474 exceeding total investment income of $8,422; however, a net realized gain of $14 and net unrealized appreciation of $1,780 on investments resulted in a net increase in net assets from operations of $742. The portfolio, with total investments at fair value of $724,129,154 and net assets of $118,723,974, showed mixed unrealized performance with gains in TechServ Operations ($1,103) and Centaur Holdings (Copperweld) ($500) offset by declines in Patriot MCN Buyer (McNichols) (-$101 and -$145) and others. Unfunded commitments totaled $80,872 with associated unrealized depreciation of $564.
- ·Credit facilities interest expense of $3,201 on average outstanding balance of $70,134 at weighted average rate of 6.45%.
- ·Interest rate sensitivity analysis shows net investment income (loss) ranging from $3,560 (up 300 bps) to $(2,683) (down 300 bps).
- ·Debt investments represent 286.1% of net assets, equity 1.2%, cash equivalents 2.2%, short-term investments 320.6%.
- ·Largest portfolio exposures: Charter Industries Holdings LLC and Patriot MCN Buyer Corp. (McNichols) at 32.2% and 33.0% of net assets respectively.
26-03-2026
Nouveau Monde Graphite Inc. filed its Form 40-F Annual Report for the fiscal year ended December 31, 2025, on March 26, 2026, confirming 160,761,539 common shares outstanding as of year-end. The report details ongoing development in mining and battery material projects like the Becancour Battery Material Plant and Matawinie Mine, with references to $50 million US 2022 convertible notes issued to Mitsui, Pallinghurst, and Investissement Quebec. No specific period-over-period financial metrics such as revenue or expenses are detailed in the provided filing excerpts.
- ·Emerging growth company status confirmed.
- ·Principal executive offices: 481 rue Brassard, Saint-Michel-des-Saints, Québec Canada J0K 3B0.
- ·U.S. agent for service: CT Corporation, 28 Liberty Street, New York, New York 10005.
26-03-2026
Philip Morris International Inc.'s 2026 DEF 14A Proxy Statement discloses 2025 compensation details for Named Executive Officers (NEOs), including maximum grant date fair values of PSUs at 200% performance led by CEO Jacek Olczak at $23,104,584. All Other Compensation for 2025 totaled $27,080 for Olczak, $1,260,178 for Stacey Kennedy (down from $2,313,631 in 2024 due to lower international assignment costs), and varied for others with some declines like Frederic de Wilde's from $253,550 in 2023. Pension value changes were driven by FX impacts and a $7,044,546 self-funded service credit purchase by Emmanuel Babeau.
- ·Approximately 630 participants in the Global Long-Term Assignment Guidelines program.
- ·Emmanuel Babeau's adjusted 2025 total compensation excluding voluntary pension contribution would be $11,815,068.
- ·No incremental cost from personal use of Company aircraft for NEOs in 2025.
26-03-2026
Philip Morris International Inc. issued Definitive Additional Proxy Materials (DEFA14A) for its 2026 Virtual Annual Shareholder Meeting on May 6, 2026, with voting deadline of 11:59 p.m. EDT on May 5, 2026. Key proposals include the election of 10 directors (all board-recommended FOR), advisory approval of executive compensation (FOR), ratification of independent auditors (FOR), and a shareholder proposal for a report on filter cleanup costs and extended producer responsibility laws (board recommends AGAINST). Proxy materials, including the Notice, Proxy Statement, and 2025 Annual Report, are available online at www.ProxyVote.com.
- ·Meeting held virtually at www.virtualshareholdermeeting.com/PM2026 starting 9:00 A.M. EDT on May 6, 2026
- ·Requests for paper/email copies of materials due by April 22, 2026
- ·Contact options for materials: www.ProxyVote.com, 1-800-579-1639, sendmaterial@proxyvote.com (include control number)
26-03-2026
Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 26, 2026, under Item 8.01 to furnish a press release announcing that its RAD and Immix units are introducing 'SARA Alive Operating Inside Immix' following SIA NPS Category Award Recognition. The press release is attached as Exhibit 99.1 and is not deemed filed or material.
- ·Filing Date: March 26, 2026
- ·Event Date: March 26, 2026
- ·Principal Executive Offices: 10800 Galaxie Avenue, Ferndale, Michigan, United States 48220
26-03-2026
Brookfield Wealth Solutions Ltd. reported total assets of $157,181 million as of Dec 31, 2025, up 12% from $139,953 million in 2024, with gross annuity sales rising 25% YoY to $19,829 million driven by retail ($15,661 million, +42%) and institutional growth. However, net income fell 31% YoY to $863 million from $1,247 million amid a 17% drop in total revenues to $11,635 million, and net premiums declined sharply to $4,487 million from $8,267 million. Adjusted equity grew 43% to $16,837 million, and total liquidity stood at $62,575 million.
- ·Corporate liquidity declined to $1,256 million as of Dec 31, 2025 from $2,035 million in 2024.
- ·Net income attributable to shareholders was $766 million in 2025, down from $1,214 million in 2024.
- ·Cash flow from operating activities decreased to $2,614 million in 2025 from $4,569 million in 2024.
26-03-2026
BlackRock Monticello Debt Real Estate Investment Trust reported a Net Asset Value of $123,154 thousand as of December 31, 2025, driven by $561,965 thousand in real estate loan investments across 25 loans and total liquidity of $213,480 thousand. However, the REIT recorded a net loss of $2,293 thousand for the year ended December 31, 2025, or $(1.21) per common share amid total expenses of $19,222 thousand exceeding revenues of $16,929 thousand. The portfolio showed strength in Senior Housing (13.1% debt yield) but weakness in Multifamily (4.5% debt yield), with weighted average LTV at 70.9%.
- ·Dividends per Class F-I and E shares: $0.9635 total ($0.8214 ordinary dividends, $0.1421 return of capital, $0 capital gain).
- ·Sources of distributions: 100% from cash flows from operating activities.
- ·Common shareholder's equity and redeemable common shares: $111,046 thousand.
- ·Adjustments to equity for NAV: Organizational/offering expenses due to affiliates $11,016 thousand; Shareholder servicing fees payable $1,092 thousand.
26-03-2026
Dorian LPG Ltd. issued a press release on March 26, 2026, providing an update on estimates for its fleet for the quarter ending March 31, 2026, disclosed under Item 7.01 Regulation FD. The press release is furnished as Exhibit 99.1 and not considered 'filed' with the SEC. The filing was signed by CFO Theodore B. Young.
- ·SEC Filing Type: 8-K (Items 7.01, 9.01)
- ·Date of Report: March 26, 2026
- ·Quarter Reference: Ending March 31, 2026
- ·Common Stock: LPG on New York Stock Exchange
26-03-2026
NovelStem International Corp. reported net income of $2,379,882 for FY 2025, a turnaround from a $3,233,042 net loss in FY 2024, primarily driven by one-time gains including $1,171,760 from disposal of an equity method investment and $1,697,024 in relief of indebtedness income. However, the company generated no administrative fee income (down from $12,000) and recorded an operating loss of $238,755 (improved from $927,922 but still negative), with cash balances critically low at $333. Total assets declined to $15,786 from $160,111, while shareholders' deficit improved to $(2,141,655) from $(5,144,375).
- ·Options granted: 100,000 per Director and 100,000 to President/Executive Chairman on April 1, 2024, exercise price $0.06.
- ·Net cash used in operating activities: $167,633 in 2025 (improved from $271,964).
- ·Proceeds from bridge loan payable (related party): $161,867 in 2025.
- ·Settlement of long-term notes payable: $2,997,025 (non-cash).
- ·Settlement of derivative liability, net of interest: $614,000 (non-cash).
26-03-2026
RedCloud Holdings plc (RCT) filed an F-1 registration statement on March 26, 2026, for its planned IPO, disclosing balance sheet data as of June 30, 2025, and comparative periods including six months ended June 30, 2025 and 2024, full years 2024 and 2023. The filing details operations across geographies such as Nigeria (NG), Argentina (AR), UK (GB), and others, with references to capitalized software development, shareholder term loans, and convertible loan agreements. No specific performance improvements or declines are quantified in the provided tags.
- ·Geographical segments: Nigeria (NG), Argentina (AR), UK (GB), Other
- ·Loan details: Unsecured Shareholder Term Loans, Convertible Loan Agreements (Tranche One drawn Feb 8, 2024; Tranche Two Mar 26, 2024)
- ·Merger Reserve and other equity components referenced for multiple periods
- ·Property, plant & equipment: Computer Equipment, Office Equipment
26-03-2026
Worthington Steel reported Q3 FY2026 net sales of $769.8 million, up 12% YoY from $687.4 million, driven by 4% higher direct volumes and 9% higher direct selling prices, though overall volume fell 7% to 817,524 tons due to 22% lower toll volumes. Operating income declined sharply to $3.1 million from $18.3 million (-83% YoY), pressured by $22.9 million higher SG&A including $15.4 million in Kloeckner acquisition fees, while adjusted EBIT fell to $20.0 million from $25.3 million. The company entered a business combination agreement launching a €11 per share tender offer for Kloeckner & Co SE, expected to close in H2 2026, and declared a $0.16 quarterly dividend payable June 26, 2026.
- ·Net cash provided by operating activities Q3 FY2026: $63.3 million (up from $53.8 million YoY)
- ·Capex Q3 FY2026: $30.0 million (up from $28.6 million YoY)
- ·Free cash flow Q3 FY2026: $33.3 million (up from $25.2 million YoY)
- ·Q3 FY2026 EPS attributable to controlling interest: $0.20 (down from $0.27); adjusted $0.27 (down from $0.35)
- ·YTD FY2026 adjusted net EPS: $1.49 (up from $1.11)
- ·Dividend record date: June 12, 2026; payment date: June 26, 2026
- ·Operates 37 facilities in seven states and 10 countries
26-03-2026
Rockwell Medical reported Q4 2025 net sales of $18.3 million, down 26% YoY from $24.7 million due to reduced purchase volume from one customer, but gross margin improved to a record-high 21% from 15% with gross profit up 8% to $3.9 million. Full-year 2025 net sales declined 32% to $69.3 million from $101.5 million, gross margin remained flat at 17%, net loss widened to $5.3 million from $0.5 million, though Adjusted EBITDA stayed positive at $0.3 million versus $5.0 million prior year and cash position rose to $25.0 million from $21.6 million amid $2.3 million Q4 operating cash flow.
- ·Extended Amended Agreement with major U.S. dialysis provider through Dec 31, 2026 with increased pricing.
- ·Signed multi-year product purchase agreement with Innovative Renal Care in July 2025.
- ·Added 30 new customers in western U.S. in Q4 2025; region now >10% of customer footprint.
- ·2026 guidance: Adjusted EBITDA $1M to $2M, positive operating cash flow.
- ·Q1-Q3 2025 net sales: $18.9M, $16.1M, $15.9M respectively.
26-03-2026
Rockwell Medical, Inc. reported net sales of $69,258 declining 31.8% YoY from $101,489 in 2024, with gross profit falling 33.1% to $11,695 and operating loss widening to $(4,691) from operating income of $608. Net loss expanded to $(5,314) from $(480), while cash and equivalents decreased to $10,711 from $15,662. However, stockholders' equity grew to $36,981 from $32,586, supported by common stock issuances raising approximately $7,800 net proceeds.
- ·Net cash used in operating activities was $659 in 2025 vs provided $4,202 in 2024.
- ·Investments available-for-sale increased to $14,286 at Dec 31, 2025 from $5,940.
- ·Common stock issuances: 4,964,636 shares in 2025 raising net $7,800; 4,718,923 shares in 2024 raising net $10,172.
- ·Deferred Consideration Paid in Connection with Evoqua Asset Acquisition: $2,371 in 2025.
- ·Stock-based compensation expense: $1,816 in 2025 vs $1,292 in 2024.
26-03-2026
Rockwell Medical, Inc. (RMTI) filed a Form 8-K on March 26, 2026, under Items 7.01 and 9.01, announcing the availability of an updated corporate presentation dated March 26, 2026, furnished as Exhibit 99.1. The disclosure is made pursuant to Regulation FD and is not deemed 'filed' for purposes of Section 18 of the Exchange Act or incorporated into other filings unless specifically referenced. The report was signed by CEO Mark Strobeck.
26-03-2026
Celcuity Inc. reported a net loss of $177,042 thousand for the year ended December 31, 2025, up 58% from $111,779 thousand in 2024, driven by total operating expenses rising 52% to $172,192 thousand with R&D up 39% to $144,995 thousand and G&A surging 200% to $27,197 thousand. However, the company significantly bolstered its liquidity with cash and equivalents increasing to $165,703 thousand from $22,515 thousand, fueled by $360,552 thousand from financing activities, while total assets doubled to $466,558 thousand. The annual report emphasizes risks around gedatolisib development under the Pfizer license, clinical trial uncertainties, and dependency on future capital raises.
- ·Convertible debt of $195,324 thousand introduced in 2025 (none in 2024).
- ·Note payable non-current increased to $126,527 thousand from $97,727 thousand.
- ·Net cash used in operating activities worsened to $(153,280) thousand from $(83,467) thousand.
- ·Investments rose to $275,794 thousand from $212,589 thousand.
- ·Total liabilities increased to $366,003 thousand from $129,504 thousand.
- ·Accumulated deficit grew to $(448,897) thousand from $(271,855) thousand.
26-03-2026
KKR Private Equity Conglomerate LLC's net increase in net assets resulting from operations surged to $1,036,882 in 2025 from $315,435 in 2024 (+228.6% YoY), propelled by $1,195,458 in net unrealized appreciation after taxes and investments at fair value growing to $9,009,449 from $3,918,519 (+129.9% YoY). However, net investment income deteriorated to a $130,718 loss from a $15,919 loss (+723% worse YoY), driven by total operating expenses ballooning to $308,929 from $97,467 (+217.0% YoY), while net realized losses widened to $27,858 from $1,243. Net assets expanded to $9,495,126 from $4,343,385 (+118.5% YoY), supported by $4,183,756 in share issuance proceeds despite $3,756,888 net cash used in operating activities from portfolio acquisitions.
- ·Dividend income net of withholding tax: $110,595 in 2025 (up 108.2% YoY from $53,104)
- ·Provision for income taxes: $82,411 in 2025 (up from $21,200)
- ·Performance participation allocation: $203,187 in 2025
- ·Net cash provided by financing activities: $4,119,564 in 2025
- ·Proceeds from disposal of or repayments from portfolio companies: $78,386 in 2025 (up from $12,708)
26-03-2026
Federal Home Loan Bank of Des Moines filed an 8-K disclosing a schedule of 17 consolidated obligations totaling $220 million in par value, traded on March 23-24, 2026, with settlement primarily on March 30, 2026. These Optional Principal Redemption bonds feature fixed constant coupon rates ranging from 4.05% to 5.80%, maturities from 2029 to 2046, and call dates starting September 2026. No prior period data or performance comparisons are provided in the filing.
- ·All bonds are Optional Principal Redemption type with Fixed Constant rate sub-type
- ·Primarily Bermudan call style (redeemable on specified recurring dates); two American style
- ·Trade dates: March 23, 2026 (7 bonds) and March 24, 2026 (10 bonds)
- ·Call dates primarily September/October 2026 or March 2027
26-03-2026
Barclays Dryrock Issuance Trust submitted its 10-K annual report for the fiscal year ended December 31, 2025, omitting standard business and financial sections per General Instruction J as a securitization trust with no common equity. Servicing participants, including Barclays Bank Delaware and Barclays Bank PLC, provided assessments confirming compliance with servicing criteria for the period January 1 to December 31, 2025, with no material noncompliance or deficiencies noted. The filing discloses ongoing antitrust litigation against Barclays Bank Delaware involving interchange fees, including historical settlements of $6.05B (2012) and $6.20B (2018), opt-out actions, and uncertainty regarding ultimate liability.
- ·No legal proceedings material to noteholders except disclosed interchange fee antitrust cases and a non-material claim against Wilmington Trust related to Tricolor Holdings securitizations.
- ·Injunctive class settlement presented for preliminary approval on November 10, 2025, with hearing scheduled for April 20, 2026.
- ·One opt-out proceeding transferred to Northern District of Illinois with trial scheduled for September 2026.
- ·Attestation reports from independent accountants confirm no material noncompliance in servicing activities.
26-03-2026
Ellington Credit Company (NYSE: EARN) announced the commencement of an underwritten public offering of unsecured notes due 2031 (the '2031 Notes'), rated 'BBB' by Egan-Jones Ratings Company. The net proceeds will be used for general corporate purposes, including funding purchases of additional assets and repaying short-term borrowings under reverse repurchase agreements. The notes are expected to list on the NYSE under ticker 'ELLA' within 30 days of issuance, with underwriters led by Piper Sandler & Co.
- ·Underwriters granted a 30-day option to purchase additional notes to cover overallotments.
- ·Preliminary prospectus dated March 23, 2026, filed with SEC.
- ·Fund is externally managed by an affiliate of Ellington Management Group, L.L.C.
26-03-2026
Allegiant Travel Company filed a 10-K/A amendment on March 26, 2026, to include Part III disclosures on directors, executive officers, compensation, and governance due to uncertainty on proxy statement timing. The filing highlights strong 2025 performance with record airline-only operating revenue of $2.5 billion (up 4.3% YoY), airline-only operating CASM excluding fuel and special charges at 8.04 cents (down 6.1% YoY on 12.6% capacity growth), and controllable completion of 99.9%, alongside announcements of a merger with Sun Country Airlines and the sale of Sunseeker Resort. NEOs earned 124% of target short-term incentives based on performance metrics, with no discretionary bonuses awarded.
- ·Announced definitive merger agreement to acquire Sun Country Airlines in January 2026.
- ·Completed sale of Sunseeker Resort on September 4, 2025.
- ·Expanded network with 54 new routes, including eight new cities.
- ·Ranked 2nd best airline among major US carriers by Wall Street Journal 2025; named by Newsweek as one of America's Most Loved Brands 2025.
- ·No delinquent Section 16(a) reports by directors and executive officers in 2025.
- ·Audit committee: Gary Ellmer, Linda A. Marvin (financial expert, chairperson), Charles W. Pollard.
26-03-2026
On March 24, 2026, Wheeler Real Estate Investment Trust, Inc. fully exercised amended and restated warrants (A&R Warrants) held by affiliates of Magnetar Financial LLC and Purpose Alternative Credit Funds, issuing 172,075 shares of common stock representing 12% of outstanding shares at an exercise price of $0.01 per share. This transaction generated minimal proceeds of approximately $1,721 but resulted in significant dilution for existing shareholders. As a result, there are no outstanding warrants remaining in the company's capital structure.
- ·A&R Warrants originally amended and restated on February 19, 2026, and set to expire on March 27, 2026.
- ·Shares issued are registered pursuant to Form S-11 (File No. 333-294263), effective March 20, 2026.
- ·Trading symbols: WHLR (Common Stock), WHLRP (Series B Preferred), WHLRD (Series D Preferred), WHLRL (Notes) on Nasdaq Capital Market.
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 50 filings
🇺🇸 More from United States
View all →March 26, 2026
US Pre-Market SEC Filings Roundup — March 26, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
Biotech Small-Cap Approvals — March 25, 2026
Biotech Small-Cap Approvals
March 25, 2026
New Drug Approvals (Original) — March 25, 2026
New Drug Approvals (Original)